Kenvue

Kenvue was established as an independent consumer health company on February 23, 2022, following its spin-off from Johnson & Johnson's consumer health division. The company's name, derived from the English word "ken" (knowledge) and the French word "vue" (sight), reflects its focus on consumer insights and well-being. Kenvue inherited a substantial portfolio of heritage brands, many with over a century of history, including those acquired through previous J&J acquisitions of companies like Pfizer Consumer Healthcare, Vogue International, and Zarbee’s.

The company's initial public offering in May 2023 was a significant financial event, raising $3.8 billion and representing the largest U.S. IPO since 2021, with an initial valuation around $41 billion. Kenvue operates in key health categories such as over-the-counter medicines, skin health and beauty, oral care, baby care, and wound care. The brand emphasizes a commitment to science-backed products that earn consumer trust, aiming to lead in categories where brand recognition and established consumer habits play a significant role.

In November 2025, Kimberly-Clark announced its intention to acquire Kenvue, a transaction expected to conclude in the second half of 2026. This proposed merger aims to create a combined entity valued at approximately $32 billion, positioning it as a leading global player in the health and wellness sector. Despite its strong market presence, Kenvue faced legal challenges, including a securities class action lawsuit in 2023 concerning disclosures about phenylephrine risks. [edit]